MX9704779A - Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5. - Google Patents

Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5.

Info

Publication number
MX9704779A
MX9704779A MX9704779A MX9704779A MX9704779A MX 9704779 A MX9704779 A MX 9704779A MX 9704779 A MX9704779 A MX 9704779A MX 9704779 A MX9704779 A MX 9704779A MX 9704779 A MX9704779 A MX 9704779A
Authority
MX
Mexico
Prior art keywords
treatment
recombinant
mediated disorders
antagonists useful
diagnostics
Prior art date
Application number
MX9704779A
Other languages
English (en)
Spanish (es)
Inventor
Robert S Ames
Edward Robert Appelbaum
Irvin M Chaiken
Richard M Cook
Mitchell Stuart Gross
Stephen Dudley Holmes
Lynette Jane Mcmillan
Timothy Wayne Theisen
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9704779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/470,110 external-priority patent/US5693323A/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of MX9704779A publication Critical patent/MX9704779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX9704779A 1994-12-23 1995-12-22 Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5. MX9704779A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number Publication Date
MX9704779A true MX9704779A (es) 1997-09-30

Family

ID=27408594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704779A MX9704779A (es) 1994-12-23 1995-12-22 Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5.

Country Status (21)

Country Link
US (1) US6129913A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0800536B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2001523083A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100391977C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE346867T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU708951B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9510499B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2208503C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ297045B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69535319T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0800536T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2277336T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI119374B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU222992B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92912I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9704779A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300787I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO324181B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ301916A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL194312B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996021000A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
PT1914244E (pt) * 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1527100B1 (en) * 2002-03-29 2009-07-01 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20070219117A1 (en) * 2003-10-27 2007-09-20 Medvet Science Pty Ltd Bidentate motif and methods of use
EP1810690B1 (en) * 2004-10-28 2012-01-18 Kyowa Hakko Kirin Co., Ltd. Anti-IL-5 receptor antibody for use in treating endometriosis.
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
JP4335286B2 (ja) 2008-02-08 2009-09-30 ファナック株式会社 部品保護機能を備えたロボット制御装置及びロボット制御方法
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
US11046782B2 (en) * 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
MX2019007642A (es) 2016-12-23 2019-09-09 Cephalon Inc Anticuerpos anti-il-5.
CN117018189A (zh) * 2017-05-26 2023-11-10 葛兰素史密斯克莱知识产权发展有限公司 生物制药组合物和相关方法
KR102709785B1 (ko) 2017-09-29 2024-09-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
WO2020119728A1 (zh) * 2018-12-12 2020-06-18 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
US20220144937A1 (en) * 2019-03-29 2022-05-12 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
IL92180A (en) * 1988-11-03 1997-04-15 Schering Corp Pharmaceutical composition for preventing or reducing eosinophilia
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA929328B (en) * 1991-12-02 1993-07-20 Fluor Corp Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
HUT67943A (en) * 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
AU1289795A (en) * 1993-11-19 1995-06-06 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
HU222992B1 (hu) 2004-01-28
NO972913L (no) 1997-08-19
FI972703A0 (fi) 1997-06-23
NO324181B1 (no) 2007-09-03
CA2208503A1 (en) 1996-07-11
EP0800536A4 (en) 2004-12-01
FI119374B (fi) 2008-10-31
NL300787I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-04-05
ES2277336T3 (es) 2007-07-01
HUT78055A (hu) 1999-07-28
HK1003651A1 (en) 1998-11-06
BR9510499B1 (pt) 2009-05-05
EP0800536A2 (en) 1997-10-15
PL194312B1 (pl) 2007-05-31
NO972913D0 (no) 1997-06-20
DE69535319D1 (de) 2007-01-11
ATE346867T1 (de) 2006-12-15
NZ301916A (en) 1999-05-28
US6129913A (en) 2000-10-10
NO2015027I1 (no) 2015-12-18
JP2001523083A (ja) 2001-11-20
CZ196397A3 (en) 1997-10-15
NL300787I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-04-05
CN100391977C (zh) 2008-06-04
CZ297045B6 (cs) 2006-08-16
EP0800536B1 (en) 2006-11-29
NO2015027I2 (no) 2016-01-04
PL321088A1 (en) 1997-11-24
DK0800536T3 (da) 2007-04-02
LU92912I2 (fr) 2016-02-16
CA2208503C (en) 2009-12-01
AU4745096A (en) 1996-07-24
WO1996021000A2 (en) 1996-07-11
WO1996021000A3 (en) 1996-09-06
CN1175263A (zh) 1998-03-04
AU708951B2 (en) 1999-08-19
DE69535319T2 (de) 2007-07-19
JP2008029355A (ja) 2008-02-14
BR9510499A (pt) 1999-03-30
FI972703L (fi) 1997-08-22

Similar Documents

Publication Publication Date Title
MX9704779A (es) Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5.
MY124219A (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
EP1749840A3 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
GB9619691D0 (en) Antibodies against E-selection
IL189629A0 (en) Compositions containing human ctla-4 antibodies
NL300238I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO1994011503A3 (en) Chimeric factor viii
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
WO2002015846A3 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
EP0967994A4 (en) IMPROVED METHOD OF TREATMENT AND DIAGNOSIS OF VEHICLE DISORDERS BY IL-5
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
HUP0001165A3 (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them
UA32602C2 (uk) Спосіб отримання губчатого заліза та установка для здійснення цього способу
PL329387A1 (en) Novel steroids, their application as medical agents, method of obtaining them, intermediate compounds appearing in the process of obtaining them and compositions containing such novel steroids
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
WO1998006431A3 (en) Method for treating diabetes
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
IL124354A0 (en) Hemoregulatory compounds
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.